Novartis Promises 14 New Big-Selling Drugs In Five Years – ValueWalk Premium

Novartis Promises 14 New Big-Selling Drugs In Five Years

Officials at drug maker Novartis AG (NYSE:NVS) say they could have at least 14 new major drugs on the market within the next five years. The drug maker is currently focusing on treatments for respiratory problems, heart problems, and cancer.

Like most other drug makers, Novartis AG (NYSE:NVS) is also facing competition as some of the company’s bestselling drugs lose their patent protection, especially the drug Diovan, which is used to treat high blood pressure. However, Novartis is expecting its newer drugs like Afinitor, which is designed to treat breast cancer, to increase sales.

Novartis Promises 14 New Big-Selling Drugs In Five Years

Some industry analysts warn that next year rival drug makers Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Biogen Idec Inc. (NASDAQ:BIIB) will be bringing out competing drugs for some of Novartis’ newer products, like Gilenya, which treats multiple sclerosis, and Lucentis, which is used for eye problems. But right now Novartis has 139 different drugs in development, and over 73 of them are new molecular entities which cover a broad range of health problems.

Novartis AG (NYSE:NVS) officials are highlighting two drugs: LCZ686 and Serelaxin, both of which would be used to treat heart failure. The drug company is expected to file for regulatory approval for Serelaxin, both in the U.S. and in Europe, early next year, although late-stage study results released Tuesday on the drug were somewhat mixed, leaving some analysts to believe that the drug maker might need to conduct additional trials to ensure that Serelaxin will be a success commercially.

The drug maker’s pharmaceuticals division expects to file for approval on nine products within the next year. Shares of the company’s stocks traded 1.3 percent higher at 57.30 francs on the Stoxx 600 Europe by early afternoon.

LEAVE A COMMENT


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds. 📈

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

Sign up now. 👇

CLICK HERE TO TRY IT OUT

 

0